Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial

INTRODUCTION: Prior to investing in a large, multicentre randomised controlled trial (RCT), the National Institute for Health Research in the UK called for an evaluation of the feasibility and value for money of undertaking a trial on intravenous immunoglobulin (IVIG) as an adjuvant therapy for seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Soares, Marta O, Welton, Nicky J, Harrison, David A, Peura, Piia, Shankar-Hari, Manu, Harvey, Sheila E, Madan, Jason, Ades, Anthony E, Rowan, Kathryn M, Palmer, Stephen J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271457/
https://www.ncbi.nlm.nih.gov/pubmed/25434816
http://dx.doi.org/10.1186/s13054-014-0649-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271457/
https://www.ncbi.nlm.nih.gov/pubmed/25434816
http://dx.doi.org/10.1186/s13054-014-0649-z

Ejemplares similares